Icosavax nabs $51M as synthetic virus heads toward clinic
A new biotech is using an artificial virus-like particle to try to vaccinate against the respiratory syncytial virus (RSV), a flu-like disease for which no …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
